E
Entrada Therapeutics, Inc. (TRDA)
NGM – Real Time Price. Currency in USD
11.93
-0.38 (-3.09%)
At close: Mar 27, 2026, 4:00 PM EDT
11.93
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:04 PM EDT
Get all premium features to the best stock analysis tool
NGM – Real Time Price. Currency in USD
11.93
-0.38 (-3.09%)
At close: Mar 27, 2026, 4:00 PM EDT
11.93
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:04 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 12.53 | 6.05 | 10 | |
| Quick ratio | 12.53 | 5.63 | 10 | |
| Debt to Equity | 0.17 | 0.30 | 9.0 | |
| Debt to Assets | 0.14 | 1.04 | 8.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.6 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | 129M | 211M | 25M | 25M |
| Gross Profit | -2M | 126M | 207M | 21M | 21M |
| Operating Income | -97M | -3M | 47M | -156M | -156M |
| Net Income | -95M | -7M | 66M | -144M | -144M |
| EBITDA | -95M | -321K | 51M | -152M | -152M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -83.77 | -142.52 | 1.0 |
| Next quarter | 71.1 | -4.12 | 5.5 |
| Current year | -1.98 | -12.8 | 1.0 |
| Next year | 20.64 | 5.8 | 7.5 |
| Weighted average score | 3.8 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -19.51 | 11.26 | 11.32 | -13.68 | 4.0 |
| Y/Y | -96.52 | -3562.77 | -3233.32 | 0.76 | 1.3 |
| 3y average | 324.82 | 285.2 | 242.28 | -28.06 | 7.8 |
| 5y average | 594.49 | 135.56 | 197.46 | -51.45 | 7.8 |
| Weighted average score | 5.2 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $91.1M significantly exceed its total debt $50.9M, ensuring strong financial flexibility
Total current assets $306.3M exceed Total current liabilities $24.5M, highlighting excellent liquidity
Debt-to-equity ratio (0.2) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$32.0M limits the company's ability to reinvest or pay down debt